160 related articles for article (PubMed ID: 32313296)
1. Identification of potential binders of the main protease 3CL
Macchiagodena M; Pagliai M; Procacci P
Chem Phys Lett; 2020 Jul; 750():137489. PubMed ID: 32313296
[TBL] [Abstract][Full Text] [Related]
2. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation.
Keretsu S; Bhujbal SP; Cho SJ
Sci Rep; 2020 Oct; 10(1):17716. PubMed ID: 33077821
[TBL] [Abstract][Full Text] [Related]
3. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
[TBL] [Abstract][Full Text] [Related]
4. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
5. Ensemble Docking Coupled to Linear Interaction Energy Calculations for Identification of Coronavirus Main Protease (3CL
Jukič M; Janežič D; Bren U
Molecules; 2020 Dec; 25(24):. PubMed ID: 33316996
[TBL] [Abstract][Full Text] [Related]
6. Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CL
Vincent S; Arokiyaraj S; Saravanan M; Dhanraj M
Front Mol Biosci; 2020; 7():613401. PubMed ID: 33425994
[TBL] [Abstract][Full Text] [Related]
7. Structural similarities between SARS-CoV2 3CL
Bafna K; Cioffi CL; Krug RM; Montelione GT
Front Chem; 2022; 10():948553. PubMed ID: 36353143
[TBL] [Abstract][Full Text] [Related]
8. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
9. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
10. Computational modeling of the bat HKU4 coronavirus 3CL
Abuhammad A; Al-Aqtash RA; Anson BJ; Mesecar AD; Taha MO
J Mol Recognit; 2017 Nov; 30(11):. PubMed ID: 28608547
[TBL] [Abstract][Full Text] [Related]
11. Human coronavirus OC43 3CL protease and the potential of ML188 as a broad-spectrum lead compound: homology modelling and molecular dynamic studies.
Berry M; Fielding B; Gamieldien J
BMC Struct Biol; 2015 Apr; 15():8. PubMed ID: 25928480
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of SARS-CoV-2 3CL
Tahir Ul Qamar M; Alqahtani SM; Alamri MA; Chen LL
J Pharm Anal; 2020 Aug; 10(4):313-319. PubMed ID: 32296570
[TBL] [Abstract][Full Text] [Related]
13. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.
Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
ACS Pharmacol Transl Sci; 2020 Oct; 3(5):1008-1016. PubMed ID: 33062953
[TBL] [Abstract][Full Text] [Related]
14. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
[TBL] [Abstract][Full Text] [Related]
15. Shape-based Machine Learning Models for the Potential Novel COVID-19 Protease Inhibitors Assisted by Molecular Dynamics Simulation.
Nayarisseri A; Khandelwal R; Madhavi M; Selvaraj C; Panwar U; Sharma K; Hussain T; Singh SK
Curr Top Med Chem; 2020; 20(24):2146-2167. PubMed ID: 32621718
[TBL] [Abstract][Full Text] [Related]
16. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
[TBL] [Abstract][Full Text] [Related]
17. Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.
Achutha AS; Pushpa VL; Suchitra S
J Proteome Res; 2020 Nov; 19(11):4706-4717. PubMed ID: 32960061
[TBL] [Abstract][Full Text] [Related]
18. Discovery of anti-SARS coronavirus drug based on molecular docking and database screening.
Chen HF; Yao JH; Sun J; Li Q; Li F; Fan BT; Yuan SG
Chin J Chem; 2004 Aug; 22(8):882-887. PubMed ID: 32313408
[TBL] [Abstract][Full Text] [Related]
19. Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease.
Bosken YK; Cholko T; Lou YC; Wu KP; Chang CA
Front Mol Biosci; 2020; 7():174. PubMed ID: 32850963
[TBL] [Abstract][Full Text] [Related]
20. Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL
Chitranshi N; Gupta VK; Rajput R; Godinez A; Pushpitha K; Shen T; Mirzaei M; You Y; Basavarajappa D; Gupta V; Graham SL
J Transl Med; 2020 Jul; 18(1):278. PubMed ID: 32646487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]